Assenagon Asset Management S.A. Sells 99,446 Shares of Harrow, Inc. (NASDAQ:HROW)

Assenagon Asset Management S.A. lessened its stake in Harrow, Inc. (NASDAQ:HROW) by 89.1% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,138 shares of the company’s stock after selling 99,446 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Harrow were worth $323,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the business. Woodmont Investment Counsel LLC lifted its holdings in Harrow by 0.5% during the fourth quarter. Woodmont Investment Counsel LLC now owns 81,400 shares of the company’s stock worth $2,731,000 after acquiring an additional 445 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Harrow by 3.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,356 shares of the company’s stock worth $582,000 after acquiring an additional 585 shares during the period. Swiss National Bank lifted its holdings in Harrow by 1.0% during the fourth quarter. Swiss National Bank now owns 59,300 shares of the company’s stock worth $1,990,000 after acquiring an additional 600 shares during the period. GF Fund Management CO. LTD. bought a new stake in Harrow during the fourth quarter worth $25,000. Finally, MetLife Investment Management LLC lifted its holdings in Harrow by 5.7% during the fourth quarter. MetLife Investment Management LLC now owns 18,908 shares of the company’s stock worth $634,000 after acquiring an additional 1,026 shares during the period. 72.76% of the stock is currently owned by institutional investors.

Harrow Stock Performance

NASDAQ:HROW opened at $31.52 on Friday. The stock has a market cap of $1.16 billion, a P/E ratio of -56.28 and a beta of 0.40. The firm’s fifty day simple moving average is $26.75 and its 200 day simple moving average is $29.38. Harrow, Inc. has a twelve month low of $19.31 and a twelve month high of $59.23. The company has a quick ratio of 0.85, a current ratio of 0.91 and a debt-to-equity ratio of 2.01.

Harrow (NASDAQ:HROW) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.40). The company had revenue of $47.83 million during the quarter, compared to analysts’ expectations of $57.00 million. Harrow had a negative return on equity of 25.01% and a negative net margin of 10.19%. As a group, research analysts predict that Harrow, Inc. will post -0.53 EPS for the current year.

Wall Street Analysts Forecast Growth

HROW has been the topic of several research reports. B. Riley lowered their target price on Harrow from $69.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. HC Wainwright boosted their target price on Harrow from $57.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, May 12th. William Blair assumed coverage on Harrow in a report on Tuesday, June 10th. They issued an “outperform” rating for the company. Finally, BTIG Research assumed coverage on Harrow in a research note on Thursday, June 12th. They issued a “buy” rating and a $62.00 target price for the company. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Harrow has an average rating of “Buy” and an average price target of $61.40.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.